Skip to search formSkip to main contentSkip to account menu

AGS-003

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Synergy of optimized administration sequence and timing of active DC immunotherapy with a PD1 checkpoint inhibitor in a mouse model of renal cell carcinoma.
31Background: AGS-003 is an immunotherapy consisting of autologous dendritic cells electroporated with amplified total tumor RNA… 
2017
2017
AGS-003 combined with sunitinib for the precision treatment of metastatic renal cell carcinoma
ABSTRACT Introduction: Unselective approaches of immunotherapy in metastatic renal cell cancer (mRCC) have been largely abandoned… 
2017
2017
Development of a novel immunotherapy for muscle invasive bladder cancer (MIBC).
402Background: AGS-003 is an autologous tumor RNA-loaded dendritic cell-based immunotherapy being tested in advanced renal cell… 
2016
2016
Argos Announces Start of Phase II AGS-003 Trial in NSCLC
The Cancer Research Network of Nebraska has initiated a phase II clinical trial of the autologous dendritic cell immunotherapy… 
2015
2015
Patient identification and eligibility insights in the synchronous metastatic RCC population: An update from the ongoing ADAPT* phase 3 study experience.
TPS4582 Background: AGS-003 is an autologous immunotherapy designed to induce a T-cell response specific to a patient’s tumor… 
2014
2014
Long-term survival in unfavorable-risk mRCC patients treated with a combination of autologous immunotherapy (AGS-003) plus sunitinib.
4524^ Background: Treatment for metastatic renal cell carcinoma (mRCC) has evolved significantly over the last decade due to… 
2014
2014
Enrollment insights in the synchronous mRCC population: An update from the ongoing ADAPT* phase 3 study experience.
TPS4599^ Background: AGS-003 is an autologous immunotherapy designed to induce a T-cell response specific to a patient’s tumor… 
Review
2013
Review
2013
Immunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now?
Immunotherapy with cytokines was the first effective treatment in metastatic renal cell carcinoma (mRCC). Long-term responders… 
2012
2012
Identification of multifunctional cytotoxic T-cell subsets as immune correlates with clinical outcomes in a phase II study of AGS-003, an autologous dendritic cell-based therapy administered to…
80 Background: AGS-003 is an autologous dendritic cell (DC) immunotherapy prepared from matured monocyte-derived DC co… 
2010
2010
Immunomonitoring of a phase I/II study of AGS-003, a dendritic cell immunotherapeutic, as first-line treatment for metastatic renal cell carcinoma.
e13006 Background: AGS-003 is an autologous immunotherapy prepared from matured monocyte-derived dendritic cells (DCs) co… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)